RESEARCH TRIANGLE PARK, N.C. , March 21, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

RESEARCH TRIANGLE PARK, N.C. , March 18, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

•  LIQ861 was well-tolerated in PAH patients at two months of treatment •  INSPIRE enrollment complete, including PK sub-study •  Anticipate submitting NDA for LIQ861 to the FDA in late 2019 RESEARCH TRIANGLE PARK, N.C. , March 11, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.

Reported positive interim LIQ861 safety data from its pivotal Phase 3 INSPIRE clinical trial Accepted by FDA into Emerging Technology Program to support review of PRINT ® technology Management to host webcast and conference call today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Feb.

RESEARCH TRIANGLE PARK, N.C. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDA NDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical

RESEARCH TRIANGLE PARK, N.C. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

RESEARCH TRIANGLE PARK, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

RESEARCH TRIANGLE PARK, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

RESEARCH TRIANGLE PARK, N.C. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the